spacer
home > ebr > Spring 2012
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2012
   
Text
PDF
BioBusiness, Finance & Communication

Patent Box Initiative

Thinking Inside the Box

Nick Beckett and Diogo Duarte de Oliveira of CMS Cameron McKenna reflect on the impact of the UK's Patent Box initiative on drug discovery, contrasting the policy with similar European initiatives.

 
view
download pdf

Strategy for UK Life Sciences

A Promising Start

Glyn Edwards of the BioIndustry Association analyses the British Government’s recently announced Strategy for UK Life Sciences, and suggests what else needs to be done to foster further growth for the industry.

 
view
download pdf

Communication Strategies

In Prime Position

Establishing a clear message and positioning strategy is essential in a climate of increasing M&A activity. Joleen Schultz at 321 Medical Launch looks at how to stand out from the crowd.

 
view
download pdf

Portfolio Management

Enhancing Strategic Focus

Translational research institutions carry unique portfolio management needs. Jan-Philipp Kruse and Markus Thunecke of Catenion, and Jesús M Hernandez at CIMA set out key strategies to best utilise funding and encourage commercial success.

 

 
view
download pdf
bullet
BioResearch and Innovation

Novel Platforms

Next Generation

Oligonucleodies have reached a pivotal moment in their development, with FDA approvals expected soon. Peter Sazani of AVI BioPharma presents novel approaches to the development of RNA-targeting therapeutics using next-generation chemistries.

 
view
download pdf

Innovation in Personalised Medicine

Unlocked Potential

Slow progress in the field of personalised medicine belies the wealth of data and tools available to researchers. Håkon Haaheim of HUNT Biosciences AS looks for a shift in perspective that could bring new results.

 
view
download pdf

Gene Genie

Steve Williamson of the North of England Cancer Network and Northumbria Healthcare Trust, and Jonathan Robinson of NewGene Ltd present a unique partnership model that spells success for developing molecular and genetic tests.

 
view
download pdf
bullet
Discovery Technology

Analytical Methods

Go With the Flow

ADCC and CDC are effective and reproducible mode of action assays that enables researchers to reliably compare the bioactivity of therapeutics, as Ulrike Herbrand and Simone Scotti of Charles River Biopharmaceutical Services GmbH discuss.

 
view
download pdf

Storage and Processing Technology

Handled with Care

As drug discovery shifts away from small molecules, Simon Sheard at Brooks Life Science Systems looks at how automated handling can be adapted to address the challenges posed by biologic samples, including storage at ultra low temperatures, processing widely variable samples and quality control.

 
view
download pdf

Screening Libraries

Full Screen Ahead

Jeffrey C Webster at AMRI presents the various types of screening libraries available and examines their advantages and pitfalls for drug discovery, as well as the strategies for executing successful screens.
 
view
download pdf

Antibody Discovery

Take the Lead

Jos Raats and Guido Jenniskens of ModiQuest Research explore how B cell selection and phage display, when used in tandem, provide a highly efficient platform for antibody selection.

 
view
download pdf
bullet
BioDevelopment and Regulatory

Regulatory Challenges

Changing of the Tides

G Susan Srivatsa of ElixinPharma navigates current guidelines for novel therapeutics and explores how these apply to the development of oligonucleotides.

 
view
download pdf

Drug Reprofiling

Old Drug, New Tricks

Attempts at reprofiling drugs include wet lab and in silico initiatives, some taking a rational approach, others opting for brute force. Jordi Naval Chamosa and José Manuel Mas of Anaxomics weigh up these strategies.

 
view
download pdf
bullet
BioRegional

Regional Focus: Denmark

Up Close and Personal

Rasmus Beedholm-Ebsen at Invest in Denmark explores the factors that make Denmark ideally placed to push forward developments in personalised medicine.

 
view
download pdf
BioManufacturing

Biomanufacturing: European CMOs

Opportunity Beckons

Big Pharma is increasingly investing in biologics, causing demand for biopharmaceutical manufacturing capacity to soar. Aiswariya Chidambaram at Frost & Sullivan surveys the current landscape and identifies where future opportunities exist for CMOs within Europe.

 
view
download pdf

Biomanufacturing: Cell Lines

Contamination Control

Virus contamination can occur in the manufacture of even the most well-characterised cell lines. Andy Bailey of ViruSure GmbH examines recent examples of this and considers how future contamination can be avoided.

 
view
download pdf

Quality Control: Analytical Methods

Good Vibrations

Todd Strother at Thermo Fisher Scientific discusses NIR spectrometry as an effective method for simple, precise and rapid testing of raw materials for biopharmaceutical manufacture, taking the identification and quantification of phosphate salts used for the manufacture of ultra-high purity cell culture buffers as an example.

 
view
download pdf
bullet
INTERVIEW

How to be a Biotech Dragon

EBR talks to Jim Reid, Chairman and CEO of Sistemic, about the status of the biotech industry.

 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare

As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from their preferred partner, Philips.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement